Dr. Stephen Pollitt is an Angel Investor. He served as Board Member at Sand Hill Angels. He has over 19 years experience in the biotechnology and pharmaceutical industries. His career began with Scios (later acquired by Johnson & Johnson) where he was in charge of host cell development for biologics heading into clinical testing. One of these products, Natrecor, received FDA approval in 2001 as a treatment for acute congestive heart failure. He served as Project Leader on several early phase drug discovery and development projects, most recently as Compound Development Team Lead for VEGF-121. He also served on the target selection committee which evaluated targets for the company's small molecule development platform. Steve is currently an independent consultant working with drug development teams at start-ups and virtual companies where he assists with management of the drug development process and molecular biology of protein expression. Steve holds a Ph.D. in Molecular Biology from Purdue University, West Lafayette, IN and a B.S. in Chemistry with honors from the University of Georgia. He was a postdoctoral fellow at SUNY, Stony Brook and a Research Assistant Professor at the University of Medicine and Dentistry of NJ in Piscataway.